Chen Weibo, Wu Junhua, Shi Hua, Wang Zhongxia, Zhang Guang, Cao Yin, Jiang Chunping, Ding Yitao
Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China ; Jiangsu Province's Key Medical Center for Hepatobiliary Surgery, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China.
School of Medicine, Nanjing University, Nanjing, Jiangsu 210093, China.
Biomed Res Int. 2014;2014:764981. doi: 10.1155/2014/764981. Epub 2014 Jun 25.
Tumor microenvironment confers drug resistance to kinase inhibitors by increasing RKT ligand levels that result in the activation of cell-survival signaling including PI3K and MAPK signals. We assessed whether HSC-LX2 coculture conferred sorafenib resistance in Huh7 and revealed the mechanism underlying the drug resistance.
The effect of LX2 on sorafenib resistance was determined by coculture system with Huh7 cells. The rescue function of LX2 supernatants was assessed by MTT assay and fluorescence microscopy. The underlying mechanism was tested by administration of pathway inhibitors and manifested by Western blotting.
LX2 coculture significantly induced sorafenib resistance in Huh7 by activating p-Akt that led to reactivation of p-ERK. LX2 secreted HGF into the culture medium that triggered drug resistance, and exogenous HGF could also induce sorafenib resistance. The inhibition of p-Akt blocked sorafenib resistance caused by LX2 coculture. Increased phosphorylation of Jak2 and Stat3 was also detected in LX2 cocultured Huh7 cells. The Jak inhibitor tofacitinib reversed sorafenib resistance by blocking Jak2 and Stat3 activation. The combined administration of sorafenib and p-Stat3 inhibitor S3I-201 augmented induced apoptosis even in the presence of sorafenib resistance.
HSC-LX2 coculture induced sorafenib resistance in Huh7 through multiple pathways: HGF/c-Met/Akt pathway and Jak2/Stat3 pathway. A combined administration of sorafenib and S3I-201 was able to augment sorafenib-induced apoptosis even in the presence of LX2 coculture.
肿瘤微环境通过增加RKT配体水平赋予激酶抑制剂耐药性,这会导致包括PI3K和MAPK信号在内的细胞存活信号激活。我们评估了HSC-LX2共培养是否赋予Huh7细胞对索拉非尼的耐药性,并揭示了耐药的潜在机制。
通过与Huh7细胞共培养系统确定LX2对索拉非尼耐药性的影响。通过MTT法和荧光显微镜评估LX2上清液的挽救功能。通过给予通路抑制剂测试潜在机制,并通过蛋白质印迹法显示。
LX2共培养通过激活p-Akt显著诱导Huh7细胞对索拉非尼的耐药性,进而导致p-ERK重新激活。LX2将HGF分泌到培养基中引发耐药性,外源性HGF也可诱导索拉非尼耐药性。抑制p-Akt可阻断LX2共培养引起的索拉非尼耐药性。在LX2共培养的Huh7细胞中还检测到Jak2和Stat3的磷酸化增加。Jak抑制剂托法替布通过阻断Jak2和Stat3激活逆转索拉非尼耐药性。即使在存在索拉非尼耐药性的情况下,索拉非尼与p-Stat3抑制剂S3I-201联合给药也能增强诱导的细胞凋亡。
HSC-LX2共培养通过多种途径诱导Huh7细胞对索拉非尼耐药:HGF/c-Met/Akt途径和Jak2/Stat3途径。即使在存在LX2共培养的情况下,索拉非尼与S3I-201联合给药也能够增强索拉非尼诱导的细胞凋亡。